How to buy Otonomy stock

Otonomy, Inc is a biotechnology business based in the US. Otonomy shares (OTIC) are listed on the NASDAQ and all prices are listed in US Dollars. Otonomy employs 56 staff and has a trailing 12-month revenue of around 0.00.

Otonomy share price

Use our graph to track the performance of OTIC stocks over time.

Otonomy shares at a glance

• Key figures

Information last updated 2021-04-22.

52-week range	$2.03 - $6.98
50-day moving average	$2.56
200-day moving average	$4.12
Wall St. target price	$5.63
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.60

Buy Otonomy shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Otonomy stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Otonomy, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Otonomy financials

Revenue TTM	$273,000
Gross profit TTM	$-915,000
Return on assets TTM	-28.72%
Return on equity TTM	-84%
Profit margin	0%
Book value	$1.37
Market capitalisation	$125.6 million

TTM: trailing 12 months

Shorting Otonomy shares

There are currently 907,594 Otonomy shares held short by investors – that's known as Otonomy's "short interest". This figure is 33.9% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting Otonomy shares can be evaluated.

Otonomy's "short interest ratio" (SIR)

Otonomy's "short interest ratio" (SIR) is the quantity of Otonomy shares currently shorted divided by the average quantity of Otonomy shares traded daily (recently around 817652.25225225). Otonomy's SIR currently stands at 1.11. In other words for every 100,000 Otonomy shares traded daily on the market, roughly 1110 shares are currently held short.

However Otonomy's short interest can also be evaluated against the total number of Otonomy shares, or, against the total number of tradable Otonomy shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Otonomy's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Otonomy shares in existence, roughly 20 shares are currently held short) or 0.0198% of the tradable shares (for every 100,000 tradable Otonomy shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Otonomy.

Find out more about how you can short Otonomy stock.

Otonomy share dividends

We're not expecting Otonomy to pay a dividend over the next 12 months.

Otonomy share price volatility

Over the last 12 months, Otonomy's shares have ranged in value from as little as $2.03 up to $6.983. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Otonomy's is 2.0381. This would suggest that Otonomy's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Otonomy overview

Otonomy, Inc. , a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc.

Frequently asked questions

• What percentage of Otonomy is owned by insiders or institutions?

  Currently 1.169% of Otonomy shares are held by insiders and 92.048% by institutions.

• How many people work for Otonomy?

  Latest data suggests 56 work at Otonomy.

• When does the fiscal year end for Otonomy?

  Otonomy's fiscal year ends in December.

• Where is Otonomy based?

  Otonomy's address is: 4796 Executive Drive, San Diego, CA, United States, 92121

• What is Otonomy's ISIN number?

  Otonomy's international securities identification number is: US68906L1052

• What is Otonomy's CUSIP number?

  Otonomy's Committee on Uniform Securities Identification Procedures number is: 68906L105